Breast Cancer

Quest Diagnostics has licensed Matrix-Bio’s biomarkers for breast cancer recurrence and plans to launch a commercial diagnostic test in early 2015.

Learn More »

Colon Cancer

We’re developing a colon cancer monitoring test using metabolite profiling that detects cancer recurrence earlier and more accurately than existing tests.

Learn More »

Investor Ready

Matrix-Bio seeks to raise $750,000 to validate our Colon Cancer Monitoring test (CCM), the first of three tests for the more than $2 billion colon cancer testing market.

Learn More »


Matrix-Bio CEO Eric Beier is a featured presenter at the 2014 Venture Summit West February 13 in Mountain View, Calif., seeking funding for new colon cancer tests.

Learn More »

Register for Updates

If you’re an investor or an oncologist interested in tracking Matrix-Bio’s progress, we invite your interest.

Register Now »


New molecular diagnostics such as DNA, RNA, and proteomics have not delivered the clinically actionable results envisioned. So why is metabolite profiling different?

Continue Reading »